Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study

Completed

Conditions studied: Acromegaly

In brief

To assess the safety and effectiveness of Somatuline® Depot (lanreotide) Injection when administered by a health care professional (HCP), the patient, the patient's partner or parent/guardian as part of their routine acromegaly care.

Key facts

Study ID

NCT00686348

Run by

Ipsen

People needed

260

Starts

2008-05-01

Expected to finish

2015-11-01

Last updated by the study team

2019-01-11

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The patient must have a clinical diagnosis of acromegaly
• The patient must be treated with Somatuline® Depot (including patients newly prescribed Somatuline® Depot)
• The patient or legally authorized representative must be able to understand the protocol and give signed informed consent. Assent from the patient should also be obtained, where appropriate. Signed informed consent and assent must be obtained before any study-related activities are conducted.

You may not qualify if…

• Symptomatic, untreated biliary lithiasis
• Known hypersensitivity to somatostatin analogs or related compounds (e.g., octreotide)

Where it is running

• Ipsen — Basking Ridge, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.